Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Inclusion Criteria:

• Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
• Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
• 18 years old or older
• Willing and able to provide informed consent
• Willing to have additional blood samples collected during routine surveillance visits

Exclusion Criteria:

• Not willing to have additional blood samples collected
• Pathology that is not consistent with colorectal adenocarcinoma